The lung microbiota in cystic fibrosis
The lung microbiota in cystic fibrosis
批准号:
7829335
负责人:
JOHN J LIPUMA
金额:
$50.0万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-01 至 2011-08-31
关键词:
AddressAgeAntibiotic TherapyAreaBioinformaticsCaringCatalogingCatalogsCessation of lifeCharacteristicsChronicClinicalCollectionCommunicable DiseasesCommunicationComplexCystic FibrosisDefense MechanismsDevelopmentDisciplineDisease ProgressionEcologyEcosystemEquipmentFoundationsGrantHealthHuman ResourcesIi-KeyImmune responseIndividualInfectionInterventionIntestinesInvestigationKnowledgeLungLung diseasesMedicalMedical RecordsMetagenomicsMethodsMicrobiologyMissionMolecularMolecular ProfilingMonitorNational Heart, Lung, and Blood InstitutePatientsPersonsPostdoctoral FellowPrevention approachPulmonary Cystic FibrosisRelative (related person)ResearchResearch Ethics CommitteesResearch PersonnelRespiratory SystemRespiratory tract structureRoleSamplingSpecimenSputumStructureSystemTaxonomyTherapeuticTimeTrainingTranslational Researchclinical phenotypecostcystic fibrosis patientsexperienceimprovedinsightmeetingsmicrobialmicrobial communitymicrobiomemicroorganismnovelpublic health relevancerepositoryrespiratoryresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This application addresses broad Challenge Area (15) Translational Science and specific Challenge Topic, 15-HL-104: Characterize the role and effects of the respiratory and/or intestinal microbiota on the presence and clinical phenotype of lung disease. The progressive lung disease that is the primary cause of illness and death in persons with cystic fibrosis (CF) is strongly influenced by immunological defense mechanisms in the airways, and a major contributor to an individual's immune response is the microorganisms that have established themselves in the airways. Currently, very little is known about the microbiota of the respiratory tract in persons with CF or the relationship of lung disease to changes in the microbial community of the airways. A mission of the National Heart, Lung and Blood Institute is to better understand the relationships between individual microbiomes and lung disease. This understanding will not only provide important insights into the causes and mechanisms of lung disease, but also offer great potential for rapid translation of research results into improved approaches for prevention and treatment of CF lung disease. The long-term objective of this project is to understand the relationship between the lung microbiota and the progression of lung disease in persons with cystic fibrosis (CF). We will analyze a large existing repository of sputum samples obtained from several hundred CF patients during the past decade. We will utilize culture-independent analysis of the microbial community in the CF lung analyses to characterize the lung microbiota of these individuals and correlate changes in airway microbial community to changes in patient clinical status. Comparison of microbial community structure within individual patients during periods of relative health and illness, and between patients with similar or different clinical status will be done to associate specific ecologic and functional characteristics of the lung microbiota with the progression of CF lung disease.
PUBLIC HEALTH RELEVANCE: Progressive lung disease, resulting from chronic infection of the airways, is the primary cause of illness and death in persons with cystic fibrosis (CF). Recent studies indicate that the number of microbial species involved in lung infection in CF (the CF lung microbiota) is much larger and more complex than previously believed. Nevertheless, currently little is known about how the structure of the lung microbiota (i.e., the precise types of species present and the relative abundance of each) or changes in this structure influence the progression of lung disease in CF. The long-term objective of this project is to understand the relationship between the lung microbiota and the progression of lung disease in persons with CF.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dynamics of airway microbiota at pulmonary exacerbation in cystic fibrosis
-
批准号:9286133
-
项目类别:
-
资助金额:$16.92万
-
财政年份:2017
-
负责人:JOHN J LIPUMA
-
依托单位:
Dynamics of airway microbiota at pulmonary exacerbation in cystic fibrosis
-
批准号:9906260
-
项目类别:
-
资助金额:$38.59万
-
财政年份:2017
-
负责人:JOHN J LIPUMA
-
依托单位:
The lung microbiota in cystic fibrosis
-
批准号:7935321
-
项目类别:
-
资助金额:$49.88万
-
财政年份:2009
-
负责人:JOHN J LIPUMA
-
依托单位:
Genes associated with epidemic Burkholderia cenocepacia
-
批准号:7384875
-
项目类别:
-
资助金额:$24.03万
-
财政年份:2007
-
负责人:JOHN J LIPUMA
-
依托单位:
Genes associated with epidemic Burkholderia cenocepacia
-
批准号:7536038
-
项目类别:
-
资助金额:$18.91万
-
财政年份:2007
-
负责人:JOHN J LIPUMA
-
依托单位:
Burkholderia sp: Identification of major clonal lineages
-
批准号:6708900
-
项目类别:
-
资助金额:$7.65万
-
财政年份:2003
-
负责人:JOHN J LIPUMA
-
依托单位:
Burkholderia sp: Identification of major clonal lineages
-
批准号:6596573
-
项目类别:
-
资助金额:$7.63万
-
财政年份:2003
-
负责人:JOHN J LIPUMA
-
依托单位:
HAEMOPHILUS INFLUENZAE B VIRULENCE: ROLE OF HAEMOCIN
-
批准号:3455354
-
项目类别:
-
资助金额:$10.78万
-
财政年份:1991
-
负责人:JOHN J LIPUMA
-
依托单位:
HAEMOPHILUS INFLUENZAE B VIRULENCE--ROLE OF HAEMOCIN
-
批准号:2064656
-
项目类别:
-
资助金额:$10.69万
-
财政年份:1991
-
负责人:JOHN J LIPUMA
-
依托单位:
HAEMOPHILUS INFLUENZAE B VIRULENCE--ROLE OF HAEMOCIN
-
批准号:2064657
-
项目类别:
-
资助金额:$11.53万
-
财政年份:1991
-
负责人:JOHN J LIPUMA
-
依托单位:
HAEMOPHILUS INFLUENZAE B VIRULENCE--ROLE OF HAEMOCIN
-
批准号:3455353
-
项目类别:
-
资助金额:$10.97万
-
财政年份:1991
-
负责人:JOHN J LIPUMA
-
依托单位:
HAEMOPHILUS INFLUENZAE B VIRULENCE: ROLE OF HAEMOCIN
-
批准号:3455352
-
项目类别:
-
资助金额:$10.55万
-
财政年份:1991
-
负责人:JOHN J LIPUMA
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: